The Second Circuit affirmed dismissal of an FCA qui tam based on allegedly faulty medical devices, an area marked for particular FCA scrutiny by the DOJ-HHS FCA Working Group, as […]
Recently a court took the rare step of granting a motion to dismiss a qui tam suit because the relator’s vague and conclusory scienter allegations failed to satisfy Rules 8 […]
In just the last week, the Texas Attorney General’s Office (“TX AG’s Office”) filed three actions against healthcare providers and entities, continuing an increasingly robust and aggressive enforcement regime that […]
During her keynote speech at the Federal Bar Association’s Qui Tam Conference, Brenna Jenny, Deputy Assistant Attorney General for the Commercial Litigation Branch, stated that robust FCA enforcement is “the […]
At the Federal Bar Association’s Qui Tam Conference, Brenna Jenny, the Deputy Assistant Attorney General of DOJ’s Commercial Litigation Branch, offered the most detailed description yet of the Trump Administration’s […]
Speaking as part of a panel at the Federal Bar Association’s annual Qui Tam Conference today, a Senior Trial Counsel at the Department of Justice (DOJ), Christelle Klovers, emphasized the […]
Last week, DOJ released its annual report detailing FCA recoveries and new cases, which can be found here. In the press release, accessible here, DOJ touts two records in fiscal […]
We have previously reported on two district court decisions from Minnesota and Texas analyzing FCA damages and penalties under the Eighth Amendment Excessive Fines Clause, with both courts finding the […]
DOJ announced that genetic testing company Illumina Inc. will pay $9.8 million to resolve allegations that it sold genomic sequencing systems with cybersecurity vulnerabilities to the various federal Departments and […]
The FCA’s qui tam provisions are intended to incentivize individuals who have legitimate information about fraud on the government that would otherwise go undetected to bring those issues forward. Increasingly, […]